No products in the cart.
Pre-made Fontolizumab benchmark antibody ( Whole mAb, anti-IFNG therapeutic antibody, Anti-IFG/IFI/IMD69 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-219
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn’s disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.
| Products Name (INN Index) | Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody |
|---|---|
| INN Name | Fontolizumab |
| Target | IFNG |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 1t3f:BA/1t04:DC:BA |
| 95-98% SI Structure | None |
| Year Proposed | 2002 |
| Year Recommended | 2003 |
| Companies | PDL BioPharma |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Autoimmune disorders,Crohn's disease,Psoriasis,Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNG |
| Package |
Previous slide
Next slide
